Vestal Point Capital LP Acquires 275,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Vestal Point Capital LP raised its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 15.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,000,000 shares of the company's stock after acquiring an additional 275,000 shares during the quarter. Vestal Point Capital LP owned approximately 2.83% of Ventyx Biosciences worth $4,380,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Bank of America Corp DE grew its position in shares of Ventyx Biosciences by 376.4% during the fourth quarter. Bank of America Corp DE now owns 4,273,442 shares of the company's stock worth $9,359,000 after purchasing an additional 3,376,446 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Ventyx Biosciences in the 4th quarter worth approximately $3,903,000. Millennium Management LLC boosted its stake in Ventyx Biosciences by 369.7% in the 4th quarter. Millennium Management LLC now owns 1,281,629 shares of the company's stock worth $2,807,000 after purchasing an additional 1,008,760 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Ventyx Biosciences by 88.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 871,527 shares of the company's stock valued at $1,909,000 after buying an additional 409,357 shares in the last quarter. Finally, Two Sigma Advisers LP raised its position in shares of Ventyx Biosciences by 72.1% during the fourth quarter. Two Sigma Advisers LP now owns 800,800 shares of the company's stock valued at $1,754,000 after buying an additional 335,400 shares during the last quarter. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Trading Up 19.0%

Shares of NASDAQ:VTYX traded up $0.29 during midday trading on Thursday, reaching $1.82. 7,994,068 shares of the company were exchanged, compared to its average volume of 1,331,142. The business's fifty day moving average is $1.21 and its two-hundred day moving average is $1.74. Ventyx Biosciences, Inc. has a one year low of $0.78 and a one year high of $5.66. The stock has a market cap of $129.51 million, a PE ratio of -0.77 and a beta of 0.73.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09. As a group, sell-side analysts expect that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.